Skip to main content
Premium Trial:

Request an Annual Quote

Gene42, SeqOne Partner for Rare Disease Diagnosis

NEW YORK (GenomeWeb) – Startups in Canada and France are combining their genomic analysis and machine learning technology in pursuit of faster, more accurate diagnoses of rare conditions.

Toronto-based Gene42, maker of software that supports precision medicine programs, is partnering with SeqOne, a French developer of a genome analysis platform, to augment gene sequences with phenotypic data from clinical encounters. This collaboration, the companies said today, will address the estimated 80 percent of rare diseases with genetic causes.

Gene42 makes PhenoTips, software that helps clinicians capture and standardize phenotypic information at the point of care. SeqOne's platform can run phenotypes through its machine learning engine to help pinpoint the gene responsible for an otherwise undiagnosed condition.

"The collaboration between SeqOne and PhenoTips creates the opportunity to accurately diagnose more patients in a shorter period of time," SeqOne CEO Nicolas Philippe said in a statement. His company is a spinout of AxLR SATT, a tech incubator in Montpellier, France.

"Capturing the doctor's medical observations in a standardized way makes it much easier to interpret the patient’s genome," added Gene42 CEO Orion Buske.

The companies said that they ran a pilot study in France in which the combination of PhenoTips and SeqOne "significantly" improved diagnostic yield and shortened interpretation time in a group of patients with rare diseases. They did not provide any data, but said they were organizing a larger and broader study to confirm the results.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.